{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=DynPort+Vaccine+Company+LLC%2C+A+GDIT+Company",
    "query": {
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T06:57:21.264Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00057525",
      "title": "A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "Anthrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhdryogel or PBS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 70,
      "start_date": "2003-04",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057525"
    },
    {
      "nct_id": "NCT00097396",
      "title": "Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumonic Plague",
        "Preventive Therapy"
      ],
      "interventions": [
        {
          "name": "rF1V vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 40,
      "start_date": "2004-11",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097396"
    },
    {
      "nct_id": "NCT01122784",
      "title": "Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plague Vaccine"
      ],
      "interventions": [
        {
          "name": "rF1V vaccine (with Adjuvant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rF1V vaccine (without Adjuvant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 402,
      "start_date": "2010-07",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2020-07-30",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01122784"
    },
    {
      "nct_id": "NCT00042094",
      "title": "Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Cell-Cultured Smallpox Vaccine compared to Dryvax®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 350,
      "start_date": "2002-03",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042094"
    },
    {
      "nct_id": "NCT00333528",
      "title": "A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Human butyrylcholinesterase (HuBChE) derived from human plasma",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 8,
      "start_date": "2007-12-01",
      "completion_date": "2008-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333528"
    },
    {
      "nct_id": "NCT00332956",
      "title": "Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "rFIV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rF1V vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rF1V vaccine 160 mcg given on Study Days 0, 56, 182",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 400,
      "start_date": "2006-05",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2011-12-02",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • San Francisco, California • West Palm Beach, Florida + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00332956"
    },
    {
      "nct_id": "NCT00098098",
      "title": "Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RECOMBINANT BOTULINUM VACCINE A/B"
      ],
      "interventions": [
        {
          "name": "rBV A/B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 44,
      "start_date": "2004-08",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2012-08-23",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098098"
    },
    {
      "nct_id": "NCT00764634",
      "title": "Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Botulism Vaccine"
      ],
      "interventions": [
        {
          "name": "Placebo (USP sterile saline for injection)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rBV A/B-40 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 440,
      "start_date": "2008-09",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-12-02",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00764634"
    },
    {
      "nct_id": "NCT00333515",
      "title": "Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Chemical Terrorism",
        "Chemical Warfare"
      ],
      "interventions": [
        {
          "name": "Human Butyrylcholinesterase (HuBChE) derived from human plasma",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2007-01-01",
      "completion_date": "2008-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333515"
    },
    {
      "nct_id": "NCT00109304",
      "title": "Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venezuelan Equine Encephalitis"
      ],
      "interventions": [
        {
          "name": "VEE 3526",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 0,
      "start_date": "2005-07",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2015-09-18",
      "last_synced_at": "2026-10-09T06:57:21.264Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109304"
    }
  ]
}